Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure patients may skip some office visits with new remote monitoring

NCT ID NCT07544771

Disease control Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a remote monitoring system called HeartLogic to standard in-person follow-up for people with heart failure who have a special defibrillator. About 578 adults will be randomly assigned to either get alerts from the device that prompt early check-ins or to continue regular office visits. The goal is to see if remote monitoring reduces deaths, unplanned hospital stays, and declines in quality of life over one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HeartLogic algorithm (remote monitoring device software)
What this could lead to
If it works, this could make heart failure management more proactive, reducing hospital stays and improving daily life for patients.
What could go wrong
This is a mid-sized trial (578 people) testing a monitoring strategy, not a new drug. The benefit may be small or not apply to all patients, and false alerts could cause unnecessary worry or visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 578 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged ≥18 years old; 2. Patients implanted with a cardiac defibrillator for less than 6 months, with or without resynchronization, enabling the HeartLogic™ algorithm; 3. Patients with a history of HF (left ventricular ejection fraction ≤40%; or at least one episode of clinical HF with NT-proBNP blood concentration ≥450 ng/L); 4. Patients with New York Heart Association Class II or III HF; 5. Patient able to comply with the protocol, including Latitude™ transmissions (including adequate connectivity), and study visits. 6. Patients with compulsory health insurance Exclusion Criteria: 1. Patients not consenting and non-compliant with remote care directions. 2. Patients with invasive remote HF monitoring device (such as CardioMems); 3. Patients with a concomitant HF device other than cardiac resynchronization, such as a ventricular assist devices or cardiac contractility modulation devices; 4. Patients on heart transplant list, or patients with a heart transplant; 5. Patients with a glomerular filtration rate \<30 ml/min/m2; 6. Participation to a concomitant study evaluating management of HF decompensation, or diuretic titration. 7. Patients enable to consent. 8. Patients receiving State Medical Aid (Aide Médicale d'Etat). 9. Pregnant or breastfeeding women. 10. Persons benefiting from a reinforced protection, namely minors, persons deprived of liberty by a judicial or administrative decision, adults under legal protection, and finally patients in emergency situations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Georges Pompidou European hospital

    NOT_YET_RECRUITING

    Paris, France

  • Hopital du Confluent

    NOT_YET_RECRUITING

    Nantes, France

  • La Pitié Salpétrière

    NOT_YET_RECRUITING

    Paris, France

  • La Timone University hospital

    NOT_YET_RECRUITING

    Marseille, France

  • Pasteur clinic

    NOT_YET_RECRUITING

    Toulouse, France

  • University hospital of Amiens

    NOT_YET_RECRUITING

    Amiens, France

  • University hospital of Brest

    NOT_YET_RECRUITING

    Brest, France

  • University hospital of Caen

    NOT_YET_RECRUITING

    Caen, France

  • University hospital of Grenoble

    NOT_YET_RECRUITING

    Grenoble, France

  • University hospital of Lille

    NOT_YET_RECRUITING

    Lille, France

  • University hospital of Nantes

    NOT_YET_RECRUITING

    Nantes, France

  • University hospital of Poitiers

    RECRUITING

    Poitiers, 86021, France

  • University hospital of Rouen

    NOT_YET_RECRUITING

    Rouen, France

  • University hospital of Toulouse

    NOT_YET_RECRUITING

    Toulouse, France

  • University hospital of Tours

    NOT_YET_RECRUITING

    Tours, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.